Literature DB >> 17131126

Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?

Nicolas Girouin1, Florence Mège-Lechevallier, Alejandro Tonina Senes, Alvine Bissery, Muriel Rabilloud, Jean-Marie Maréchal, Marc Colombel, Denis Lyonnet, Olivier Rouvière.   

Abstract

UNLABELLED: The purpose of this study was to evaluate the accuracy of prostate cancer localization with simple visual diagnostic criteria using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). A total of 46 consecutive patients with biopsy-proven prostate cancer underwent prostate 1.5 T MRI with pelvic phased-array coils before prostatectomy. Besides the usual T2-weighted sequences, a 30-s DCE sequence was acquired three times after gadoterate injection. On DCE images, all early enhancing lesions of the peripheral zone were considered malignant. In the central gland, only early enhancing lesions appearing homogeneous or invading the peripheral zone were considered malignant. Three readers specified the presence of cancer in 20 prostate sectors and the location of distinct tumors. Results were compared with histology; p < 0.05 was considered significant. For localization of cancer in the sectors, DCE imaging had a significantly higher sensitivity [logistic regression, odds ratio (OR): 3.9, p < 0.0001] and a slightly but significantly lower specificity (OR: 0.57, p < 0.0001). Of the tumors >0.3 cc, 50-60% and 78-81% were correctly depicted with T2-weighted and DCE imaging, respectively. For both techniques, the depiction rate of tumors >0.3 cc was significantly influenced by the Gleason score (most Gleason </=6 tumors were overlooked), but not by the tumor volume.
CONCLUSION: DCE-MRI using pelvic phased-array coils and simple visual diagnostic criteria is more sensitive for tumor localization than T2-weighted imaging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131126     DOI: 10.1007/s00330-006-0478-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  40 in total

1.  Assessment of the risk of positive surgical margins with pelvic phased-array magnetic resonance imaging in patients with clinically localized prostate cancer: a prospective study.

Authors:  M Soulié; R Aziza; G Escourrou; P Seguin; C Tollon; L Molinier; J Bachaud; F Joffre; P Plante
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

2.  3 Tesla magnetic resonance imaging of the prostate with combined pelvic phased-array and endorectal coils; Initial experience(1).

Authors:  B Nicolas Bloch; Neil M Rofsky; Ronaldo H Baroni; Robert P Marquis; Ivan Pedrosa; Robert E Lenkinski
Journal:  Acad Radiol       Date:  2004-08       Impact factor: 3.173

3.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging.

Authors:  Aliya Qayyum; Fergus V Coakley; Ying Lu; Jeffrey D Olpin; Louis Wu; Benjamin M Yeh; Peter R Carroll; John Kurhanewicz
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

Review 4.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

Review 5.  EAU guidelines on prostate cancer.

Authors:  G Aus; C C Abbou; M Bolla; A Heidenreich; H-P Schmid; H van Poppel; J Wolff; F Zattoni
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

6.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging.

Authors:  Oguz Akin; Evis Sala; Chaya S Moskowitz; Kentaro Kuroiwa; Nicole M Ishill; Darko Pucar; Peter T Scardino; Hedvig Hricak
Journal:  Radiology       Date:  2006-03-28       Impact factor: 11.105

7.  Prostate cancer staging: should MR imaging be used?--A decision analytic approach.

Authors:  G J Jager; J L Severens; J R Thornbury; J J de La Rosette; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  2000-05       Impact factor: 11.105

Review 8.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

9.  Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI.

Authors:  Fabian Kiessling; Matthias Lichy; Rainer Grobholz; Melanie Heilmann; Nabeel Farhan; Maurice Stephan Michel; Lutz Trojan; Joerg Ederle; Ulrich Abel; Hans-Ulrich Kauczor; Wolfhard Semmler; Stefan Delorme
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

10.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; J O Barentsz
Journal:  AJR Am J Roentgenol       Date:  1996-04       Impact factor: 3.959

View more
  37 in total

Review 1.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

2.  [The relevance of magnetic resonance imaging (MRI) for the detection and exclusion of prostate cancer].

Authors:  J Stattaus; M Forsting
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

Review 3.  Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective.

Authors:  Ananthakrishnan Sivaraman; Kulthe Ramesh Seetharam Bhat
Journal:  Indian J Surg Oncol       Date:  2017-01-23

4.  Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?

Authors:  Daniel Junker; Fabian Steinkohl; Veronika Fritz; Jasmin Bektic; Theodoros Tokas; Friedrich Aigner; Thomas R W Herrmann; Michael Rieger; Udo Nagele
Journal:  World J Urol       Date:  2018-08-04       Impact factor: 4.226

5.  Detection of Clinically Significant Prostate Cancer: Short Dual-Pulse Sequence versus Standard Multiparametric MR Imaging-A Multireader Study.

Authors:  Borna K Barth; Pieter J L De Visschere; Alexander Cornelius; Carlos Nicolau; Hebert Alberto Vargas; Daniel Eberli; Olivio F Donati
Journal:  Radiology       Date:  2017-03-27       Impact factor: 11.105

6.  Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.

Authors:  Lian-Ming Wu; Zi-Zhou Zhao; Xiao-Xi Chen; Qing Lu; Shi-Teng Suo; Qiang Liu; Jiani Hu; E Mark Haccke; Jian-Rong Xu
Journal:  Br J Radiol       Date:  2016-04-19       Impact factor: 3.039

7.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

8.  Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI.

Authors:  Olivier Rouvière; Nicolas Girouin; Ludivine Glas; Alexandre Ben Cheikh; Albert Gelet; Florence Mège-Lechevallier; Muriel Rabilloud; Jean-Yves Chapelon; Denis Lyonnet
Journal:  Eur Radiol       Date:  2009-08-19       Impact factor: 5.315

9.  Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer.

Authors:  Oguz Akin; Christopher C Riedl; Nicole M Ishill; Chaya S Moskowitz; Jingbo Zhang; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-04       Impact factor: 5.315

Review 10.  Prostate focused ultrasound focal therapy--imaging for the future.

Authors:  Olivier Rouvière; Albert Gelet; Sébastien Crouzet; Jean-Yves Chapelon
Journal:  Nat Rev Clin Oncol       Date:  2012-08-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.